Previous close | 8.30 |
Open | 8.30 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 49.00 |
Expiry date | 2024-08-16 |
Day's range | 8.30 - 8.30 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab